Margaret Moline, PhD, Executive Director, Neurology Business Group at Eisai discusses her work developing the first insomnia treatment to be approved by the FDA in the past five years. She talks about the importance of sleep, sleep hygiene and the increased prevalence of insomnia due to the COVID-19 pandemic.
Margaret Moline, PhD, is currently an Executive Director and the International Project Team Lead/Global Medical Lead for the lemborexant clinical development program at Eisai Inc. Specializing in insomnia clinical trials and sleep disorders in women, Dr. Moline has brought five neuroscience New Drug Application submissions to the FDA. Dr. Moline also specializes in Alzheimer’s disease clinical trials and served as International Project Team Leader for Aricept from 2005-2011. With Eisai’s strong neurology pipeline, including investigational sleep-wake disorders and Alzheimer’s disease treatments, Dr. Moline is using her skills to help move science forward in areas about which she is passionate.
During her academic career in the Department of Psychiatry at New York-Presbyterian/Weill Cornell Medical College, she conducted research in basic human circadian rhythms, jet lag, premenstrual dysphoric disorder, and circadian rhythm abnormalities in psychiatric disorders.
An author on more than 60 peer-reviewed journal articles, Dr. Moline is a member of the external advisory board at the Center for Circadian Biology at the University of California at San Diego. She holds a PhD in Physiology from Harvard University and an undergraduate degree from Cornell University, also in Physiology.